Medicine and Dentistry
Positron Emission Tomography-Computed Tomography
88%
Fluorodeoxyglucose F 18
55%
Polyethylene Terephthalate
34%
Bone Scintigraphy
34%
Technetium-99
34%
Fluorine-18
30%
Single-Photon Emission Computed Tomography
30%
Neoplasm
29%
Sentinel Node
27%
Cancer
25%
Gamma Camera
24%
Fluorodeoxyglucose
22%
Positron Emission Tomography
21%
Single Photon Emission Computed Tomography-Computed Tomography
20%
Colorectal Carcinoma
19%
Standardized Uptake Value
19%
Lymphoscintigraphy
18%
Breast Imaging
16%
Breast Cancer
16%
Bone Metastasis
15%
Diseases
14%
Medronic Acid
14%
Prostate Cancer
14%
Sentinel-Node Mapping
13%
Gallium 68
13%
Melanoma
13%
Bone Disease
13%
Low Drug Dose
11%
Biopsy Technique
11%
Diagnostic Accuracy
10%
Computer Assisted Tomography
10%
Malignant Neoplasm
8%
Recurrent Disease
8%
Primary Tumor
8%
Radioactive Tracer
7%
Squamous Cell Carcinoma
7%
Prostate Specific Membrane Antigen
7%
Carcinoembryonic Antigen
7%
Metastatic Carcinoma
6%
Rectum Cancer
6%
Helix
6%
Abdominoperineal Resection
6%
Patient Assessment
6%
Skeleton Malformation
6%
Hybrid Imaging
6%
Patient with Overweight
6%
Minimal Residual Disease
6%
Hepatocellular Carcinoma
6%
Metabolic Rate
6%
Diagnosis of Parkinson's Disease
6%
Keyphrases
Positron Emission Tomography-computed Tomography (PET-CT)
100%
Single-photon Emission Computed Tomography (SPECT)
35%
18F-FDG PET-CT
27%
Sentinel Lymph Node Mapping
26%
Parkinson's Disease
24%
Gamma Camera
22%
Standardized Uptake Value
21%
SPECT-CT
20%
Coincidence Imaging
20%
18F-DOPA PET
19%
Dual Head
19%
18F-fluorodeoxyglucose (18F-FDG)
19%
Lymphoscintigraphy
18%
Bone Scintigraphy
18%
Patients with Breast Cancer
16%
Positive Predictive Value
15%
Negative Predictive Value
15%
CT Findings
14%
Fluorodeoxyglucose
14%
99mTc-phytate
14%
FDG Uptake
13%
Lymphoma
13%
18F-fluorodeoxyglucose Positron Emission Tomography (18F-FDG PET)
13%
CT System
13%
18F-fluoride PET
13%
Skeletal Disorders
13%
CT Pattern
13%
High-grade Prostate Cancer
13%
Marijuana
13%
Hodgkin Disease
13%
Regular Users
13%
18F-fluorodeoxyglucose PET
13%
LRRK2 mutation
13%
Positron Emission Tomography
13%
Mutation Carriers
13%
Δ9-tetrahydrocannabinol (Δ9-THC)
13%
Non-Hodgkin Lymphoma
13%
Extranodal Involvement
13%
Sentinel Lymph Node
12%
Malignancy
12%
Planar Images
12%
Head-mounted Camera
11%
Tumor
11%
Diagnostic Accuracy
11%
Molecular Breast Imaging
10%
Low-dose CT
10%
Consecutive Patients
10%
Recurrent Colorectal Cancer
10%
Hybrid Imaging
10%
Leucine-rich Repeat Kinase 2 (LRRK2)
10%